NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free TRDA Stock Alerts $14.17 -0.18 (-1.25%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$13.67▼$14.5150-Day Range$11.58▼$16.0452-Week Range$10.62▼$18.44Volume105,311 shsAverage Volume77,956 shsMarket Capitalization$476.11 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Entrada Therapeutics alerts: Email Address Entrada Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside48.2% Upside$21.00 Price TargetShort InterestBearish10.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.16Based on 8 Articles This WeekInsider TradingAcquiring Shares$63,200 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.54) to ($2.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.12 out of 5 starsMedical Sector594th out of 938 stocksPharmaceutical Preparations Industry268th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, Entrada Therapeutics has a forecasted upside of 48.2% from its current price of $14.17.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.06% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 22.9, which indicates bearish sentiment.Change versus previous monthShort interest in Entrada Therapeutics has recently decreased by 1.10%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRDA. Previous Next 3.4 News and Social Media Coverage News SentimentEntrada Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Entrada Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Entrada Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have bought 103.94% more of their company's stock than they have sold. Specifically, they have bought $63,200.00 in company stock and sold $30,990.00 in company stock.Percentage Held by InsidersOnly 7.58% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from ($1.54) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -54.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -54.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Entrada Therapeutics Stock (NASDAQ:TRDA)Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More TRDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRDA Stock News HeadlinesMarch 27, 2024 | insidertrades.comPeter S. Kim Acquires 3,180 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockMarch 22, 2024 | insidertrades.comInsider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Purchases 900 Shares of StockMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 27, 2024 | finance.yahoo.comDirector Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)March 27, 2024 | americanbankingnews.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Acquires 3,180 Shares of StockMarch 20, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for Entrada Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TRDA)March 19, 2024 | finance.yahoo.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's EstimatesMarch 19, 2024 | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC WainwrightMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 18, 2024 | markets.businessinsider.comEntrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical PipelineMarch 13, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)March 13, 2024 | finanznachrichten.deEntrada Therapeutics, Inc.: Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | benzinga.comRecap: Entrada Therapeutics Q4 EarningsMarch 13, 2024 | globenewswire.comEntrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 23, 2024 | benzinga.comEntrada Therapeutics Stock (NASDAQ:TRDA) Insider TradesJanuary 29, 2024 | finance.yahoo.com‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 StocksJanuary 8, 2024 | finance.yahoo.comAmicus (FOLD) Issues Preliminary Revenue Results for FY23January 6, 2024 | msn.comOppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform RecommendationJanuary 3, 2024 | finance.yahoo.comBEAM Stock Rallies More Than 25% in 3 Months: What Next?January 3, 2024 | finance.yahoo.comEntrada Therapeutics Promotes Nathan J. Dowden to PresidentDecember 28, 2023 | finance.yahoo.comEntrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 SharesDecember 20, 2023 | finance.yahoo.comAnavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAADecember 20, 2023 | finance.yahoo.comRoche's (RHHBY) sBLA for Xolair Gets FDA Priority Review TagDecember 11, 2023 | benzinga.comEntrada Therapeutics Stock (NASDAQ:TRDA) Dividends: History, Yield and DatesDecember 11, 2023 | finance.yahoo.comPfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EUNovember 29, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDANovember 29, 2023 | finance.yahoo.comImmunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study DataSee More Headlines Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2023Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TRDA CUSIPN/A CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees159Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$22.00 Low Stock Price Target$20.00 Potential Upside/Downside+48.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,680,000.00 Net Margins-5.18% Pretax Margin9.34% Return on Equity-2.89% Return on Assets-1.39% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.33 Sales & Book Value Annual Sales$129.01 million Price / Sales3.69 Cash FlowN/A Price / Cash FlowN/A Book Value$7.26 per share Price / Book1.95Miscellaneous Outstanding Shares33,600,000Free Float31,054,000Market Cap$476.11 million OptionableNot Optionable Beta-0.52 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Dipal Doshi (Age 48)CEO & Director Comp: $902.08kMr. Nathan J. Dowden (Age 53)President & COO Comp: $654.6kDr. Natarajan Sethuraman Ph.D. (Age 62)Chief Scientific Officer Comp: $654.6kMr. Kory James Wentworth CPA (Age 44)CFO & Treasurer Dr. Jared Cohen J.D.Ph.D., General CounselMs. Kerry Robert M.S.Senior Vice President of PeopleMs. Karla MacDonaldChief Corporate Affairs OfficerMr. Kevin Healy Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsNeoleukin TherapeuticsNASDAQ:NLTXStoke TherapeuticsNASDAQ:STOKLarimar TherapeuticsNASDAQ:LRMRAltimmuneNASDAQ:ALTDianthus TherapeuticsNASDAQ:DNTHView All CompetitorsInsiders & InstitutionsPeter S KimBought 3,180 shares on 3/25/2024Total: $42,484.80 ($13.36/share)Peter S KimBought 704 shares on 3/21/2024Total: $9,320.96 ($13.24/share)Peter S KimBought 900 shares on 3/19/2024Total: $11,394.00 ($12.66/share)Vanguard Group Inc.Bought 44,849 shares on 3/11/2024Ownership: 3.192%Wellington Management Group LLPBought 2,128 shares on 3/5/2024Ownership: 3.140%View All Insider TransactionsView All Institutional Transactions TRDA Stock Analysis - Frequently Asked Questions Should I buy or sell Entrada Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRDA shares. View TRDA analyst ratings or view top-rated stocks. What is Entrada Therapeutics' stock price target for 2024? 2 brokers have issued 12-month price objectives for Entrada Therapeutics' shares. Their TRDA share price targets range from $20.00 to $22.00. On average, they predict the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 48.2% from the stock's current price. View analysts price targets for TRDA or view top-rated stocks among Wall Street analysts. How have TRDA shares performed in 2024? Entrada Therapeutics' stock was trading at $15.09 at the beginning of 2024. Since then, TRDA stock has decreased by 6.1% and is now trading at $14.17. View the best growth stocks for 2024 here. When is Entrada Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TRDA earnings forecast. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) issued its quarterly earnings results on Monday, March, 6th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.04. Entrada Therapeutics had a negative net margin of 5.18% and a negative trailing twelve-month return on equity of 2.89%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Entrada Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (9.02%), Price T Rowe Associates Inc. MD (9.02%), Vanguard Group Inc. (3.19%), Vanguard Group Inc. (3.19%), Wellington Management Group LLP (3.14%) and Northern Trust Corp (0.60%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, John F Crowley, Kory James Wentworth, Natarajan Sethuraman, Nathan J Dowden, Nerissa Kreher and Peter S Kim. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRDA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.